Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price shot up 4.4% during trading on Monday . The stock traded as high as $7.42 and last traded at $7.42, with a volume of 81,286 shares changing hands. The stock had previously closed at $7.11.

Several research firms have commented on KPTI. Jefferies Group cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating and set a $14.00 target price on the stock. in a research note on Wednesday, June 1st. Raymond James Financial Inc. began coverage on shares of Karyopharm Therapeutics in a research note on Friday, May 27th. They set an “outperform” rating and a $13.00 target price on the stock. Wedbush reissued an “outperform” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, June 10th. Canaccord Genuity reissued a “buy” rating and set a $20.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, April 6th. Finally, Leerink Swann lowered their target price on shares of Karyopharm Therapeutics from $36.00 to $18.00 in a research note on Tuesday, March 15th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $19.50.

The stock’s market capitalization is $265.74 million. The company has a 50-day moving average of $8.26 and a 200 day moving average of $8.28.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Monday, May 9th. The company reported ($0.75) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by $0.01. On average, equities analysts predict that Karyopharm Therapeutics Inc. will post ($3.09) EPS for the current year.

In related news, major shareholder Ltd Chione sold 31,868 shares of the company’s stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $8.24, for a total transaction of $262,592.32. Following the transaction, the insider now owns 8,980,000 shares in the company, valued at approximately $73,995,200. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

An institutional investor recently raised its position in Karyopharm Therapeutics stock. Wells Fargo & Company MN increased its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 1,133.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 134,886 shares of the company’s stock after buying an additional 123,951 shares during the period. Wells Fargo & Company MN owned approximately 0.38% of Karyopharm Therapeutics worth $1,787,000 as of its most recent filing with the SEC.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.